NCT06571487 Growth Hormone Resistance of Beta-cells A
| NCT ID | NCT06571487 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Missouri-Columbia |
| Condition | Gestational Diabetes |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-10-22 |
| Primary Completion | 2028-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2025-10-22 with a primary completion date of 2028-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the research study is to better understand how beta-cells (cells in the pancreas that make insulin and help regulate blood sugar) respond to growth hormone in people with a personal history of gestational diabetes (high blood sugar in pregnancy) at the University of Missouri. The aim of the study is to advance understanding of how growth hormone affects beta-cells and risk factors for developing gestational diabetes.
Eligibility Criteria
Inclusion Criteria: * Singleton, full term pregnancy within the past 5 years * Body mass index ≥18.5 kg/m2 and \<45.0 kg/m2 Group specific inclusion criteria: * Gestational Diabetes Group: History of gestational diabetes in the most recent pregnancy * Control Group: no history of gestational diabetes Exclusion Criteria: * Pregnant, planning to become pregnant during the study, or breastfeeding * Current diagnosis or history of type 1 or type 2 diabetes * Use of medications that can impact the study outcomes (e.g., GLP-1 receptor agonists) * History of bariatric surgery * Known, uncontrolled hypothyroidism * History of intracranial hypertension, including papilledema, or a condition that increases the risk of developing intracranial hypertension, such as Turner Syndrome, Prader-Willi Syndrome, or renal impairment * Current cancer or cancer that has been in remission less than 5 years * First degree relative with diabetes diagnosis * Evidence of significant anemia or significant end organ dysfunction (e.g., liver, kidney, heart disease) * Alcohol use disorder, use of controlled substances, or smoking \>2 cigarettes per day * Greater than 3% weight loss within three months of screening or engaged in regular (≥3 days per week), continuous moderate- or high-intensity exercise of ≥30 min duration * Mentally disabled persons, prisoners, and persons with inability to grant voluntary informed consent
Contact & Investigator
Bettina Mittendorfer, PhD
PRINCIPAL INVESTIGATOR
University of Missouri-Columbia
Frequently Asked Questions
Who can join the NCT06571487 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 45 Years, studying Gestational Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06571487 currently recruiting?
Yes, NCT06571487 is actively recruiting participants. Contact the research team at ahmc4@health.missouri.edu for enrollment information.
Where is the NCT06571487 trial being conducted?
This trial is being conducted at Columbia, United States.
Who is sponsoring the NCT06571487 clinical trial?
NCT06571487 is sponsored by University of Missouri-Columbia. The principal investigator is Bettina Mittendorfer, PhD at University of Missouri-Columbia. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.